Kailera Therapeutics, Inc. Common Stock (KLRA) - Total Assets
Based on the latest financial reports, Kailera Therapeutics, Inc. Common Stock (KLRA) holds total assets worth $1.21 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see KLRA cash flow conversion for how efficiently the company converts equity into cash flow.
Kailera Therapeutics, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Kailera Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Kailera Therapeutics, Inc. Common Stock (KLRA) share price today for real-time trading data and today's change.
Kailera Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Kailera Therapeutics, Inc. Common Stock's total assets of $1.21 Billion consist of 80.5% current assets and 19.5% non-current assets. Explore Kailera Therapeutics, Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.2% |
| Accounts Receivable | $2.73 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Kailera Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kailera Therapeutics, Inc. Common Stock's current assets represent 80.5% of total assets in 2025, a decrease from 99.5% in 2024.
- Cash Position: Cash and equivalents constituted 23.2% of total assets in 2025, down from 98.2% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Kailera Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Kailera Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
USA | $1.08 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
USA | $1.21 Billion |
|
LegoChem Biosciences Inc
KQ:141080
|
Korea | ₩652.93 Billion |
Kailera Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.11 | 9.67 | - |
| Quick Ratio | 11.11 | 9.67 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $845.52 Million | $475.48 Million | - |
Kailera Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Kailera Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.90 |
| Latest Market Cap to Assets Ratio | 2.17 |
| Asset Growth Rate (YoY) | 288.0% |
| Total Assets | $692.29 Million |
| Market Capitalization | $1.51 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kailera Therapeutics, Inc. Common Stock's assets at a significant premium (2.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kailera Therapeutics, Inc. Common Stock's assets grew by 288.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kailera Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Kailera Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $692.29 Million | +287.96% |
| 2024-12-31 | $178.44 Million | -- |
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more